Updates are available Correction dated 2024-01-12
Click to view Correction: https://doi.org/10.1136/rmdopen-2021-001629corr1
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Bae, Sang-Cheol https://orcid.org/0000-0003-4658-1093
Bass, Damon https://orcid.org/0000-0003-2480-5674
Curtis, Paula https://orcid.org/0000-0001-9808-5468
Chu, Myron https://orcid.org/0000-0001-5763-5603
DeRose, Kathleen https://orcid.org/0000-0002-1056-3400
Ji, Beulah https://orcid.org/0000-0002-9944-348X
Kurrasch, Regina https://orcid.org/0000-0002-2820-8423
Lowe, Jenny https://orcid.org/0000-0002-8565-2723
Meizlik, Paige https://orcid.org/0000-0002-2237-8552
Roth, David A https://orcid.org/0000-0001-8356-0457
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01597622 at ClinicalTrials.govnct01345253 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
SAT0193 A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARS
https://doi.org/10.1136/annrheumdis-2020-eular.5783
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
https://doi.org/10.1136/rmdopen-2021-001669
nct01484496 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
https://doi.org/10.1007/s40268-021-00369-w
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
https://doi.org/10.1136/rmdopen-2025-005444
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol
https://doi.org/10.1136/lupus-2024-001144
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
106 Effects of belimumab on corticosteroid use in a pivotal phase iii, randomised, placebo controlled study in subjects with systemic lupus erythematosus in north east asia
https://doi.org/10.1136/lupus-2017-000215.106
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
https://doi.org/10.1007/s00296-024-05667-5
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
https://doi.org/10.1136/rmdopen-2021-001669
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
https://doi.org/10.1136/annrheumdis-2017-211631
nct01597622 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-001118
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
https://doi.org/10.1136/rmdopen-2025-005444
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2020-000438
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
https://doi.org/10.1136/lupus-2018-000288
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study
https://doi.org/10.1136/annrheumdis-2017-eular.5235
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
https://doi.org/10.1136/lupus-2020-000459
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
https://doi.org/10.1136/lupus-2023-kcr.109
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
https://doi.org/10.1007/s00296-024-05667-5
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting
https://doi.org/10.1136/rmdopen-2025-006061
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
nct01345253 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
SAT0193 A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARS
https://doi.org/10.1136/annrheumdis-2020-eular.5783
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
https://doi.org/10.1136/rmdopen-2021-001669
nct01484496 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
https://doi.org/10.1007/s40268-021-00369-w
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
https://doi.org/10.1136/rmdopen-2025-005444
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol
https://doi.org/10.1136/lupus-2024-001144
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
106 Effects of belimumab on corticosteroid use in a pivotal phase iii, randomised, placebo controlled study in subjects with systemic lupus erythematosus in north east asia
https://doi.org/10.1136/lupus-2017-000215.106
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
https://doi.org/10.1007/s00296-024-05667-5
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
https://doi.org/10.1136/rmdopen-2021-001669
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
https://doi.org/10.1136/annrheumdis-2017-211631
nct01597622 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
https://doi.org/10.1136/lupus-2022-000830
POS1156 PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS – TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6006
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-001118
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
https://doi.org/10.1136/rmdopen-2025-005444
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.69
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2020-000438
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
https://doi.org/10.1136/lupus-2018-000288
POS0547 BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4849
SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study
https://doi.org/10.1136/annrheumdis-2017-eular.5235
POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.5428
OP0052 PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.6142
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
https://doi.org/10.1136/lupus-2020-000459
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
https://doi.org/10.1136/lupus-2023-kcr.109
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
https://doi.org/10.1136/lupus-2023-kcr.71
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting
https://doi.org/10.1136/rmdopen-2025-006061
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
https://doi.org/10.1007/s00296-024-05667-5
AB1079 BELIMUMAB VERSUS PLACEBO IMPROVES DISEASE ACTIVITY AND REDUCES CUMULATIVE GLUCOCORTICOID DOSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO WERE TREATMENT RESPONDERS: RESULTS OF A LARGE INTEGRATED ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.1843
Documents that mention this clinical trial
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
https://doi.org/10.1136/rmdopen-2021-001629
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
https://doi.org/10.1136/lupus-2022-elm2022.128
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
SAT0193 A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARS
https://doi.org/10.1136/annrheumdis-2020-eular.5783
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
https://doi.org/10.1136/rmdopen-2021-001669
-
Funding
Funding for this research was provided by:
GSK
- License Information
